Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06700841 IR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06700841: IR, MR1, MR2, MR1_fed | EXPERIMENTAL | Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4 |
| PF-06700841: MR1, MR2, IR, MR1_fed | EXPERIMENTAL | Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4 |
| PF-06700841: MR2, IR, MR1, MR1_fed | EXPERIMENTAL | Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4 |
| PF-06700841: IR, MR1, MR2, MR2_fed | EXPERIMENTAL | Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4 |
| PF-06700841: MR1, MR2, IR, MR2_fed | EXPERIMENTAL | Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4 |
| PF-06700841: MR2, IR, MR1, MR2_fed | EXPERIMENTAL | Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4 |
| PF-06700841 MR3 (Dose A) or matching placebo | EXPERIMENTAL | Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition |
| PF-06700841 MR3 (Dose B) or matching placebo | EXPERIMENTAL | Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition |
| PF-06700841 MR3 (Dose C) or matching placebo | EXPERIMENTAL | Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition |
| Name | Type | Description |
|---|---|---|
| PF-06700841 IR | DRUG | Immediate release formulation |
| PF-06700841 MR1 | DRUG | Modified release formulation 1 |
| PF-06700841 MR2 | DRUG | Modified release formulation 2 |
| PF-06700841 MR3 | DRUG | Modified release formulation 3 |
| Placebo | OTHER | Matching placebo |
Inclusion Criteria: * Healthy male and female participants between 18 -55 years of age. * BMI of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). * Participants who are willing and able to comply with all scheduled visits, treatment * plan, laboratory tests, lifestyle considerations, a...
PF-06700841 IR is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development for use in healthy participants. The drug is being studied to evaluate its pharmacokinetics and safety after single and multiple oral doses as modified release formulations.
The molecular target of PF-06700841 IR has not been disclosed in available clinical trial information. The drug is a small molecule being studied in healthy participants to assess its pharmacokinetics and safety profile.
PF-06700841 IR is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's pharmacokinetics and safety in healthy participants.
PF-06700841 IR is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, which studied the drug in healthy participants.
PF-06700841 IR has one completed clinical trial, NCT04580797, titled "Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations." This Phase 1 study enrolled 36 healthy participants in the United States.
PF-06700841 IR is a modified release formulation of the investigational drug PF-06700841. The "IR" designation indicates an immediate release version, which is being studied to evaluate its pharmacokinetics and safety in healthy participants.